As J&J's oral IL-23 takes on So­tyk­tu, one-year fol­low-up da­ta show dura­bil­i­ty: #AAD24

John­son & John­son un­veiled long-term ex­ten­sion da­ta on Sat­ur­day for a pro­gram it hopes can com­pete with Bris­tol My­ers Squibb’s So­tyk­tu in plaque pso­ri­a­sis.

Re­sults from the Phase IIb study show the drug, known as JNJ-2113 and co-de­vel­oped with Pro­tag­o­nist Ther­a­peu­tics, is able to main­tain much of its skin-clear­ing ef­fects to one year. The da­ta build on a 16-week read­out re­leased in Ju­ly 2023, and ex­pand­ed in the New Eng­land Jour­nal of Med­i­cine last month, which showed that JNJ-2113 hit on all pri­ma­ry and sec­ondary end­points in five dos­ing reg­i­mens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER